Program
LPM6690176
A development code.
Its studies are mostly in Colorectal Neoplasms, led by Luye Pharma Group.
Furthest: phase 2, since Dec 9, 20252 company-led studies, 2 open or runningNext primary completion: Dec 31, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Luye Pharma Group | 22 open or running | phase 2since Dec 9, 2025 | Jan 26, 2024 | Dec 31, 2028phase 2 · NCT07391566 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 26, 2024First study: phase 1 study in Advanced Solid TumorFirst studyNCT06240546 · 102 planned · China
- Dec 9, 2025Phase 2 study in Colorectal NeoplasmsPhase 2 reachedNCT07391566 · 99 planned · China
Ahead
- Dec 31, 2028Primary completion: phase 2 study in Colorectal NeoplasmsNCT07391566
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07391566Colorectal Neoplasms · China | 2 | Not yet recruiting | Dec 31, 2028 | 99 |
| NCT06240546Advanced Solid Tumor · China | 1 | Recruiting | Feb 2026 | 102 |
How it is read
Names in the registry
- “LPM6690176”, 2 entries
Codes read as this program: LPM6690176.
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.